Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure;Análisis coste-beneficio del uso de espironolactona en el tratamiento de la insuficiencia cardíaca crónica

Revista Espanola de Cardiologia

Volumn 54, Issue 2, 2001, Pages 175-180

  Soto Álvarez, Javier ^b   González Vílchez, Francisco ^a  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^b SEARLE   (Spain)

Author keywords

Analysis; Cost benefit; Heart failure; Spironolactone

Indexed keywords

DIGITOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; COST BENEFIT ANALYSIS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NATIONAL HEALTH SERVICE;

EID: 0343832166     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(01)76288-4     Document Type: Article

References (34)

1. Sáenz de la Calzada C. Insuficiencia cardíaca. Un problema de salud pública. An Med Interna (Madrid) 1999; 16: 551-552.
2. Rodríguez F, Guallar-Castillón P, Banegas JR, Rey J. Trends in hospitalization and mortality for heart failure in Spain, 1980-1993. Eur Heart J 1997; 18: 1771-1779.
3. Stewart AL, Greenfeld S, Hays RD, Wells K, Rogers WH, Berry SD et al. Functional status and well-being of patients with chronic conditions: results from the medical outcomes study. JAMA 1989; 262: 907-913.
4. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121: 951-957.
5. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after onset of congestive heart failure in Framingham Heart Study sublects. Circulation 1993; 88: 107-115.
6. Brotons C, Moral I, Ribera A, Pérez G, Cescant P, Bustins M et al. Tendencias de la morbimortalidad por insuficiencia cardíaca en Cataluña. Rev Esp Cardiol 1998; 51: 972-976.
7. Villar F, Banegas JR, Rodríguez F, Rey J. Descenso de la mortalidad cardiovascular en España sus comunidades autónomas (1975-1992). Med Clin (Barc) 1998; 110: 321-327.
8. García JA, Moreno F, Lombardía F, Sáenz C. Estudio clínico de las causas de insuficiencia cardíaca en 100 pacientes mayores de 65 años. Rev Clin Esp 1988; 183: 20-33.
9. Sáez T, Suárez C, Blanco F, Gabriel R. Epidemiología de las enfermedades cardiovasculares en a población anciana española. Rev Esp Cardiol 1998; 51: 864-873.
10. Rodriguez F, Del Rey J. La prevention primordial y el control poblacional de la insuficiencia cardíaca. Rev Esp Cardiol 198; 51: 977-978.
11. Tello R, Sáenz C, Gómez C. Manejo clínico de la insuficiencia cardíaca en el viejo. Rev Esp Cardiol 1995; 48 (Supl 3): 16-21.
12. Dargie HJ, McMurray JJV, McDonagh TA. Heart failure-implications of the true size of the problem. J Intern Med 1996; 239: 309-315.
13. Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc 1990; 38: 1290-1295.
14. Agudo P, Montoto C, Contreras E, Casado O, Conthe P. Inadecuado manejo terapéutieo en pacientes con insuficiencia cardíaca: estudio de los reingresos en un hospital general. An Med Intern (Madrid) 1999; 16: 557-561.
15. McMurray J, McDonagh T, Morrison CE, Dargie HJ. The growing problem of heart failure in Scottish hospitals. Br Heart J 1993; 69: P73-P74.
16. O'Connell JE, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994; 13: S107-S112.
17. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71: 3A-11A.
18. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35: 30-34.
19. Borghi C, Boschi S, Ambrosicni E, Melandri G, Branzi A, Magneni B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33: 40-45.
20. The RALES investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. The Randomized Aldactone Evaluation Study (RALES). Am J Cardiol 1996; 78: 902-907.
21. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pérez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
22. Lázaro de Mercado P. Evaluación socioeconómica de la práctica clínica cardiológica. Rev Esp Cardiol 1997; 50: 428-443.
23. Suárez P, Gabarro N, Gómez J, Millán J. Evaluation de la calidad asistencial en la insuficiencia cardíaca. An Med Interna (Madrid) 1999; 16: 553-556.
24. Base de datos de costes sanitarios. Barcelona: SOIKOS 1999.
25. Catálogo de Especialidades Farmacéuticas. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos, 1999.
26. McMurray J, Dargie HJ. Trends in hospitalization for chronic heart failure in the United Kingdom. Eur Heart J 1992; 13 (Supl): 350-352.
27. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States 1973-1986. Evidence for increasing population prevalence. Arch Intern Med 1990; 150: 769-773.
28. Haldemen GA, Croft JB, Giles WH, Rashidae A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999; 137: 352-360.
29. Karon BL. Concise review for primary-care physicians. Diagnosis and outpatient management of congestive heart failure. Mayo Clin Proc 1995; 70: 1080-1085.
30. Dinkel R, Büchner K. Holtz J. Chronic heart failure. Socio-economic relevance in the Federal Republic of Germany. Munch Med Weschr 1989; 131: 686-689.
31. Eriksson H. Heart failure: a growing public health problem. J Intern Med 1995; 237: 135-141.
32. McMurray J, Hart W. The economic impact of heart failure on the UK National Health Service. Eur Heart J 1993; 14 (Supl): 133-137.
33. Antoñanzas F, Antón F, Juárez CA, Echevarría L. Costes de la insuficiencia cardíaca crónica en España. An Med Interna (Madrid) 1997; 14: 9-14.
34. Zannad F, Briancon S, Juilliere Y, Mertes P-M, Villamot JP, Alla F et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: The EPICAL study. J Am Coll Cardiol 1999; 33: 734-742.